DGAP-News: FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity
These are the first and only devices authorized by the FDA for endoscopic sleeve gastroplasty (ESG) and endoscopic bariatric revision.
- These are the first and only devices authorized by the FDA for endoscopic sleeve gastroplasty (ESG) and endoscopic bariatric revision.
- The Apollo ESG and Apollo REVISE systems offer a compelling mix of effectiveness, safety, durability, and convenience for treatment of patients with obesity, said Chas McKhann, President and CEO of Apollo.
- The authorization of these new endoscopic systems represents a major step forward in addressing the global obesity epidemic.
- The systems are used with a dual channel endoscope (Apollo ESG and Apollo REVISE) or single channel endoscope (Apollo ESG Sx and Apollo REVISE Sx).